Efficacy and safety of prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage: a systematic review and meta-analysis

被引:8
|
作者
Pan, Rui [1 ]
Cheng, Jinping [2 ]
Lai, Kelin [1 ]
Huang, Qing [3 ]
Wu, Hui [1 ]
Tang, Yamei [2 ]
机构
[1] Huizhou Hlth Sci Polytech, Dept Nursing, Huizhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurol, Guangzhou 510120, Guangdong, Peoples R China
[3] Huizhou Hlth Sci Polytech, Dept Basic Courses, Huizhou, Guangdong, Peoples R China
基金
国家重点研发计划;
关键词
Intracranial hemorrhage; Vitamin K antagonists; Prothrombin complex concentrate; Meta-analysis; FRESH-FROZEN PLASMA; INTERNATIONAL NORMALIZED RATIO; FACTOR-IX COMPLEX; INTRACEREBRAL HEMORRHAGE; ANTICOAGULATION REVERSAL; WARFARIN; GUIDELINES; MANAGEMENT; COAGULOPATHY; ENLARGEMENT;
D O I
10.1007/s10072-019-3726-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Prothrombin complex concentrate (PCC) is the treatment of choice in vitamin K antagonist-associated intracranial hemorrhage (VKA-ICH). However, the efficiency and safety associated with their use remain unclear. Aims This study aimed to assess the current evidence of the clinical outcomes in patients with VKA-ICH treated with or without PCC. Summary of review A meta-analysis was conducted. Two randomized controlled trials and 19 observational studies were included. PCC use demonstrated a significant increased likelihood of international normalized ratio (INR) normalization (OR=3.76; 95% CI 1.74-8.12), shortened time to INR correction (MD=-1.30; 95% CI -2.08 to -0.53) and reduction of hematoma expansion (HE) rate (OR=0.37; 95% CI 0.23-0.60). Although PCC use revealed a statistical reduction at 30-day mortality (OR=0.62; 95% CI 0.50-0.78), the result was inconsistent with mortality at discharge (OR=1.03; 95% CI 0.68-1.57) and 90-day follow-up (OR=0.50; 95% CI 0.24-1.07), both of which yielded no significant difference. When subgroup analyses were performed focus on PCC only treatment with FFP, no statistically significant difference was observed in 30-day mortality (OR=0.43; 95% CI 0.11-1.71) as well. Besides, significant difference was not found in neurologic improvement at discharge (OR=1.85; 95% CI 0.32-10.75), 30-day follow-up (OR=3.00; 95% CI 0.93-9.70), or 90-day follow-up (OR=1.55; 95% CI 0.84-2.86). No statistically significant difference was noted in the risk of thromboembolism following PCC administration (OR=0.61; 95% CI 0.23-1.63). Conclusions PCC use for VKA-ICH reversal was associated with a significant reduction in INR and HE rate, without an increased risk of thromboembolic events. However, this reduction was not associated with improvement in neurologic deficits or overall survival. Well-designed randomized trials with special considerations to the aspect are necessary.
引用
收藏
页码:813 / 827
页数:15
相关论文
共 50 条
  • [1] Efficacy and safety of prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage: a systematic review and meta-analysis
    Rui Pan
    Jinping Cheng
    Kelin Lai
    Qing Huang
    Hui Wu
    Yamei Tang
    Neurological Sciences, 2019, 40 : 813 - 827
  • [2] Prothrombin Complex Concentrate for Vitamin K Antagonist-Associated Intracranial Hemorrhage - Global Evidence and the Japanese Perspective -
    Yasaka, Masahiro
    Brainsky, Andres
    Toyoda, Kazunori
    CIRCULATION JOURNAL, 2017, 81 (11) : 1564 - +
  • [3] Anticoagulation reversal in vitamin K antagonist-associated intracerebral hemorrhage: a systematic review
    Ko, Darae
    Razouki, Zayd
    Otis, James
    Marulanda-Londono, Erika
    Hylek, Elaine M.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2018, 46 (02) : 227 - 237
  • [4] Prothrombin complex concentrate for vitamin K antagonist reversal in traumatic intracranial hemorrhage
    Beynon, Christopher
    Nofal, Mohammed
    Rizos, Timolaos
    Laible, Mona
    Sakowitz, Oliver W.
    Unterberg, Andreas W.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2020, 79 : 197 - 202
  • [5] Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis
    Brekelmans, Marjolein P. A.
    van Ginkel, Kim
    Daams, Joost G.
    Hutten, Barbara A.
    Middeldorp, Saskia
    Coppens, Michiel
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2017, 44 (01) : 118 - 129
  • [6] 3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and Meta-analysis
    Puchstein, Dorothea
    Kork, Felix
    Schochl, Herbert
    Rayatdoost, Farahnaz
    Grottke, Oliver
    THROMBOSIS AND HAEMOSTASIS, 2023, 123 (01) : 40 - 53
  • [7] Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis
    Abdoellakhan, Rahat Amadkhan
    Miah, Ishita Parveen
    Khorsand, Nakisa
    Meijer, Karina
    Jellema, Korne
    NEUROCRITICAL CARE, 2017, 26 (01) : 64 - 69
  • [8] Safety and efficacy of fixed versus variable-dose prothrombin complex concentrate for emergent reversal of vitamin K antagonists: A systematic review and meta-analysis
    Condeni, Melanie Smith
    Weant, Kyle A.
    Neyens, Ron R.
    Eriksson, Evert A.
    Miano, Todd A.
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2024, 77 : 91 - 105
  • [9] Efficacy and safety of anticoagulation in atrial fibrillation patients with intracranial hemorrhage: A systematic review and meta-analysis
    Zhou, Qiang
    Liu, Xiang
    Yang, Xian
    Huang, Xiao-Hui
    Wu, Yan-Zi
    Tao, Ying-Ying
    Wei, Meng
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [10] Use of Prothrombin Complex Concentrate for Vitamin K Antagonist Reversal before Surgical Treatment of Intracranial Hemorrhage
    Wong, Yun
    CLINICAL MEDICINE INSIGHTS-CASE REPORTS, 2011, 4 : 1 - 6